Now, a study presented at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) has confirmed this theory. The results of the study indicated that antioagulant use in prostate cancer patients lowered prostate cancer mortality by more than 50%.
The study cohort consisted of 5,295 men with localized adenocarcinoma of the prostate who underwent treatment with either radical prostatectomy (n = 3,523) or radiotherapy (n = 1772).
Within this group, 37% (1,982 patients) received either warfarin (n = 428), clopidogrel (n = 287), enoxaparin (n = 26), aspirin (n = 1649), or a combination (n = 408) at the time of enrollment or during the follow-up period.
After a median follow-up of 59 months (~5 years), prostate cancer mortality was significantly lower in patients who used anticoagulants than in nonusers (1% vs. 4% at 7 years and 4% vs. 10% at 10 years; P<.01).
Further analysis by anticoagulant type indicated that the observed benefit was primarily due to the aspirin use.
Source: American Society for Radiation Oncology (ASTRO) 52nd Annual Meeting: Abstract 270. To be presented November 3, 2010.
Please visit healthreason.com for more health related articles.